Cutaneous Adverse Events of Osimertinib in Diverse Patient Populations with EGFR-mutated Non-Small Cell Lung Cancer: A Retrospective Cohort Analysis

Daniel S Alicea; Emily Miao; Peter Ch'en; Steven W Tuckman; Nitin Ohri; Balazs Halmos; Haiying Cheng; Matthew Lee; Beth N McLellan

doi:10.1016/j.jaad.2024.10.088

Cutaneous Adverse Events of Osimertinib in Diverse Patient Populations with EGFR-mutated Non-Small Cell Lung Cancer: A Retrospective Cohort Analysis

J Am Acad Dermatol. 2024 Nov 14:S0190-9622(24)03204-3. doi: 10.1016/j.jaad.2024.10.088. Online ahead of print.

Authors

Daniel S Alicea¹, Emily Miao², Peter Ch'en², Steven W Tuckman³, Nitin Ohri⁴, Balazs Halmos⁵, Haiying Cheng⁵, Matthew Lee⁵, Beth N McLellan⁶

Affiliations

¹ Division of Dermatology, Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York.
² Albert Einstein College of Medicine, Bronx, NY.
³ Department of Pharmacy, Montefiore Medical Center.
⁴ Department of Radiation Oncology, Montefiore Medical Center, Montefiore Einstein Comprehensive Cancer Center (MECCC), Albert Einstein College of Medicine, Bronx, NY.
⁵ Department of Medical Oncology, Montefiore Medical Center, Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, New York.
⁶ Division of Dermatology, Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York. Electronic address: [email protected].

PMID: 39549841
DOI: 10.1016/j.jaad.2024.10.088

No abstract available

Keywords: Cutaneous adverse event; Epidermal growth factor receptor inhibitors; Non-Small cell lung cancer; oncodermatology; osimertinib; skin of color.